NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

液體活檢市場(按癌症類型/應用類型分類)-價格/市場規模趨勢展望,行政顧問建議,自定義預測分析(2021-2025)

Liquid Biopsy Markets by Cancer Type and by Usage Type with Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2021-2025

出版商 Howe Sound Research 商品編碼 995094
出版日期 內容資訊 英文 444 Pages
商品交期: 最快1-2個工作天內
價格
液體活檢市場(按癌症類型/應用類型分類)-價格/市場規模趨勢展望,行政顧問建議,自定義預測分析(2021-2025) Liquid Biopsy Markets by Cancer Type and by Usage Type with Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2021-2025
出版日期: 2021年03月09日內容資訊: 英文 444 Pages
簡介

目前,正在通過液體活檢和體外血液測試開發和傳播用於癌症DNA的特定技術,並且正在對癌症診斷進行一場革命。這項技術為所有類型的癌症開闢了廣泛的篩查可能性。

在本報告中,我們分析了液體活檢(液體活檢)的未來技術進步和市場增長前景,並分析了技術概述,主要應用領域,對未來醫學領域的影響以及最近的主要用途。發佈動向,主要公司和主要產品的概況,未來市場趨勢展望(至2024年),按癌症類型,應用和地區劃分的詳細趨勢,新的冠狀病毒感染(COVID)-19)我們將向您發送信息,例如影響爆發。

目錄

i。液體活檢市場:戰略形勢邏輯和冠狀病毒病(COVID-19)的影響

ii。對行政營銷,銷售和業務開發人員的建議

iii。給管理顧問和投資顧問的建議

第1章簡介,市場定義

第2章市場概述

  • 在動態市場中進入公司
    • 學術研究室
    • 診斷測試開發人員
    • 基因組分析儀供應商
    • 製藥/試劑供應商
    • 獨立實驗室
    • 國家/公共實驗室
    • 醫院實驗室
    • 從業人員實驗室
    • 審計機構
    • 認證機構
  • 活檢應用
    • 癌症
    • 癌前病變
    • 炎症狀態
  • 活檢部位
  • 活檢分析:現狀分析
  • 癌症證據:液體活檢技術
    • 液體活檢技術概述
    • 反恐委員會的作用 ctDNA:它可以成為主流嗎?
    • 外來體和微泡:新生物正在形成
    • 多人遊戲
  • 目前正在製定癌症治療方案
    • 液體活檢引入的問題:雙重診斷
    • 癌症篩查的市場機會
    • 癌症管理與診斷
    • 引進階段:未來前景
    • 液體活檢的可能性
  • 產業結構
    • 醫院檢查的市場份額
    • 規模經濟
    • 從業人員實驗室
    • 醫生和POCT

第3章市場趨勢

  • 推動市場增長的因素
    • 無創遊戲規則改變者
    • 降低成本的效果
    • 提高準確性
    • 廣泛的潛在用途
    • 老年人口
  • 制約市場增長的因素
    • 低價
    • 缺乏標準
    • 協議抗性
    • 初始安裝成本
    • 新的冠狀病毒感染(COVID-19)
  • 儀器儀表和自動化
    • 檢驗設備:獲得市場份額的關鍵
    • 生物信息學的作用
  • 診斷技術的發展
    • 下一代測序:推動革命
    • NGS(下一代序列)對定價的影響
    • 藥理基因組學:診斷和治療的整合
    • CGES檢查:開拓新世界
    • 生物芯片/基於巨磁阻的測定

第4章液體活檢:最新進展

  • 本節的重要性及其使用方法

第5章主要公司簡介

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

第6章全球液體活檢診斷市場

  • 國家分析:概述
  • 按癌症類型分析:概述
  • 按應用程序分析:概述

第7章:全球液體活檢診斷市場:癌症

  • 乳腺癌
  • 大腸癌
  • 宮頸癌
  • 肺癌
  • 前列腺癌
  • 其他

第8章全球液體活檢診斷市場:按應用

  • 放映
  • 診斷
  • 治療
  • 監控

附錄

  • 美國醫療保健系統:實驗室費用展望(2021)
目錄

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread SCREENING FOR ALL TYPES OF CANCERS WITH A BLOOD TEST.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has JUST MOVED OUT OF THE DEVELOPMENT PHASE AND INTO THE GROWTH PHASE. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Liquid Biopsy Market - Strategic Situation Analysis & Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Liquid Biopsy?
  • 1.2 The Sequencing Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Liquid Biopsy
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Genomic Instrumentation Supplier
      • 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4 Pharmaceutical/Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Lab
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Using Biopsies
    • 2.2.1 Cancer
    • 2.2.2 Precancerous conditions
    • 2.2.3 Inflammatory conditions
  • 2.3 Biopsy Sites
  • 2.4 The Situation Today - Biopsy Analysis
  • 2.5 Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1 The Big Picture on Liquid Biopsy Technology
    • 2.5.2 The Role of CTCs
      • 2.5.2.1 Types of CTCs
      • 2.5.2.2 CellSearch Detection- Ultimate Sensitivity
      • 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
      • 2.5.2.4 Maintrac Detection - The Microscope
      • 2.5.2.5 Other Methods
    • 2.5.3 ctDNA - Going Mainstream?
    • 2.5.4 Exosomes and Micro Vesicles - New Kid on the Block
    • 2.5.5 The Multiple Play
  • 2.6 Cancer Treatment Protocol Under Siege
    • 2.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
    • 2.6.2 The Cancer Screening Market Opportunity
      • 2.6.2.1 GRAIL - What Is It?
    • 2.6.3 Cancer Management vs. Diagnosis
      • 2.6.3.1 The Role of Risk Assessment
      • 2.6.3.2 Managing Therapy
      • 2.6.3.3 Monitoring Disease - What Is It?
    • 2.6.4 Phases of Adoption - Looking into The Future
    • 2.6.5 The Promise of Liquid Biopsy
  • 2.7 Structure of Industry Plays a Part
    • 2.7.1 Hospital Testing Share
    • 2.7.2 Economies of Scale
      • 2.7.2.1 Hospital vs. Central Lab
    • 2.7.3 Physician Office Lab's
    • 2.7.4 Physician's and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Non Invasive Game Changer
    • 3.1.2 Lower Cost
    • 3.1.3 Greater Accuracy
    • 3.1.4 Wide Range of Potential Uses
    • 3.1.5 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 Lower prices
    • 3.2.2 Lack of Standards
    • 3.2.3 Protocol Resistance
    • 3.2.4 Initial Adoption Cost
    • 3.2.5 COVID-19
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
      • Bio-Techne to Acquire Asuragen for up to $320M
      • Personalis Broadens Liquid Biopsy Offering
      • Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
      • Delfi Diagnostics Plans Multi-Cancer Screening Test
      • Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
      • Liquid Biopsy NGS Panels - Diverse Test Claims
      • CMS Colon Cancer Screening Memo Bodes Well for Assays
      • Natera Liquid Biopsy Test Coverage to Expand
      • Freenome Closes Financing to Support Early Cancer Detection Trial
      • C$2.6M Liquid Biopsy Initiative
      • NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
      • Liquid Biopsy Shows Promise as Screen for Cancers
      • Inivata launches RaDaR™ for the detection of residual disease and recurrence
      • Liquid Biopsy Assay Detects 50+ Types of Cancer
      • Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
      • Guardant Health Liquid Biopsy Expands Medicare Coverage
      • Aethlon Medical Lands Grant for Exosome Isolation Device
      • Biolidics to Develop Liquid Biopsy Breast Cancer Test
      • Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
      • Exact Sciences buys Genomic Health
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
      • Thrive to Develop Earlier Detection of Multiple Cancer Types
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning
      • Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
      • Natera Commercializes Tumor Whole Exome Sequencing from Plasma
      • Sienna Buys Liquid Biopsy & Exosome Isolation Technology
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

6. The Global Market for Liquid Biopsy Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Cancer - Overview
    • 6.2.1 Table - Global Market by Cancer
    • 6.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Cancer - Base Year
    • 6.2.4 Chart - Global Market by Cancer - End Year
    • 6.2.5 Chart - Global Market by Cancer - Share by Year
    • 6.2.6 Chart - Global Market by Cancer - Segments Growth
  • 6.3 Global Market by Usage - Overview
    • 6.3.1 Table - Global Market by Usage
    • 6.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Usage - Base Year
    • 6.3.4 Chart - Global Market by Usage - End Year
    • 6.3.5 Chart - Global Market by Usage - Share by Year
    • 6.3.6 Chart - Global Market by Usage - Segments Growth

7. Global Liquid Biopsy Diagnostic Markets - By Cancer

  • 7.1 Breast
    • 7.1.1 Table Breast - by Country
    • 7.1.2 Table Breast - by Country, Price and Volume
    • 7.1.3 Chart - Breast Growth
  • 7.2 Colorectal
    • 7.2.1 Table Colorectal - by Country
    • 7.2.2 Table Colorectal - by Country, Price and Volume
    • 7.2.3 Chart - Colorectal Growth
  • 7.3 Cervical
    • 7.3.1 Table Cervical - by Country
    • 7.3.2 Table Cervical - by Country, Price and Volume
    • 7.3.3 Chart - Cervical Growth
  • 7.4 Lung
    • 7.4.1 Table Lung - by Country
    • 7.4.2 Table Lung - by Country, Price and Volume
    • 7.4.3 Chart - Lung Growth
  • 7.5 Prostate
    • 7.5.1 Table Prostate - by Country
    • 7.5.2 Table Prostate - by Country, Price and Volume
    • 7.5.3 Chart - Prostate Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.1.2 Table Other - by Country, Price and Volume
    • 7.6.2 Chart - Other Growth

8. Global Liquid Biopsy Diagnostic Markets - by Usage

  • 8.1 Screening
    • 8.1.1 Table Screening - by Country
    • 8.1.2 Chart - Screening Growth
  • 8.2 Diagnostic
    • 8.2.1 Table Diagnostic - by Country
    • 8.2.2 Chart - Diagnostic Growth
  • 8.3 Therapy
    • 8.3.1 Table Therapy - by Country
    • 8.3.2 Chart - Therapy Growth
  • 8.4 Monitor
    • 8.4.1 Table Monitor - by Country
    • 8.4.2 Chart - Monitor Growth

Appendices

  • I. United States Medicare System: 2021 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Biopsy Sites
  • Table 4 Advantages of Liquid Biopsy in Screening Market
  • Table 5 Outlook - Phases of Liquid Biopsy Adoption by Year
  • Table 6 Five Factors Driving Growth
  • Table 7 Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 - Global Market by Region
  • Table 11 Global Market by Cancer
  • Table 12 Global Market by Usage
  • Table 13 Breast by Country
  • Table 14 Breast by Country Price and Volume
  • Table 15 Colorectal by Country
  • Table 16 Colorectal by Country Price and Volume
  • Table 17 Cervical by Country
  • Table 18 Cervical by Country Price and Volume
  • Table 19 Lung by Country
  • Table 20 Lung by Country Price and Volume
  • Table 21 Prostate by Country
  • Table 22 Prostate by Country Price and Volume
  • Table 23 Other by Country
  • Table 24 Other by Country Price and Volume
  • Table 25 Screening by Country
  • Table 26 Diagnostic by Country
  • Table 27 Therapy by Country
  • Table 28 Monitor by Country
  • Table 29 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 Comparison of Liquid Biopsy Classes
  • Figure 3 Characteristics of Different Vesicle Types
  • Figure 4 Percentage of World Population Over 65
  • Figure 5 Global Market Regional Share Chart
  • Figure 6 Global Market by Cancer - Base vs. Final
  • Figure 7 Global Market by Cancer Base Year
  • Figure 8 Global Market by Cancer End Year
  • Figure 9 Cancer Share by Year
  • Figure 10 Cancer Segments Growth
  • Figure 11 Global Market by Usage - Base vs. Final
  • Figure 12 Global Market by Usage Base Year
  • Figure 13 Global Market by Usage End Year
  • Figure 14 Usage Share by Year
  • Figure 15 Usage Segments Growth
  • Figure 16 Breast Growth
  • Figure 17 Colorectal Diagnostics Growth
  • Figure 18 Cervical Growth
  • Figure 19 Lung Growth
  • Figure 20 Prostate Growth
  • Figure 21 Other Growth
  • Figure 22 Screening Growth
  • Figure 23 Diagnostic Growth
  • Figure 24 Therapy Growth
  • Figure 25 Monitor Growth